# 1 Genetically Engineered Proteins with Two Active Sites for Enhanced Biocatalysis and

## 2 Synergistic Chemo- and Biocatalysis

3

4 Sandra Alonso<sup>1,10</sup>, Gerard Santiago<sup>2,10</sup>, Isabel Cea-Rama<sup>3,10</sup>, Laura Fernandez-Lopez<sup>1</sup>, Cristina

5 Coscolín<sup>1</sup>, Jan Modregger<sup>4</sup>, Anna K. Ressmann<sup>4</sup>, Mónica Martínez-Martínez<sup>1</sup>, Helena Marrero<sup>1</sup>,

6 Rafael Bargiela<sup>5,6</sup>, Marcos Pita<sup>1</sup>, Jose L. Gonzalez-Alfonso<sup>1</sup>, Manon L. Briand<sup>7</sup>, David Rojo<sup>8</sup>, Coral

7 Barbas<sup>8</sup>, Francisco J. Plou<sup>1</sup>, Peter N. Golyshin<sup>5,6</sup>, Patrick Shahgaldian<sup>7</sup>, Julia Sanz-Aparicio<sup>3,11,\*</sup>, Víctor

8 Guallar<sup>2,9,11,\*</sup> and Manuel Ferrer<sup>1,11,\*</sup>

9 <sup>1</sup>Institute of Catalysis, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.

<sup>2</sup>Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain. <sup>3</sup>Department of Crystallography

11 & Structural Biology, Institute of Physical Chemistry "Rocasolano", CSIC, 28006 Madrid, Spain.

<sup>4</sup>EUCODIS Bioscience GmbH, 1030 Vienna, Austria. <sup>5</sup>School of Natural Sciences, Bangor University,

13 LL57 2UW Bangor, UK. <sup>6</sup>Centre for Environmental Biotechnology, Bangor University, LL57 2UW

14 Bangor, UK. <sup>7</sup>University of Applied Sciences and Arts Northwestern Switzerland, School of Life

15 Sciences, Institute of Chemistry and Bioanalytics, CH-4132 Muttenz, Switzerland. <sup>8</sup>Centro de

16 Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad CEU San Pablo, 28668

17 Boadilla del Monte, Madrid, Spain. <sup>9</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA),

18 08010 Barcelona, Spain. <sup>10</sup>These authors contributed equally: Sandra Alonso, Gerard Santiago, and

19 Isabel Cea-Rama. <sup>11</sup>These authors equally coordinated the work: Julia Sanz-Aparicio, Víctor Guallar

20 and Manuel Ferrer. \*e-mail: xjulia@iqfr.csic.es (J.S-A.); victor.guallar@bsc.es (V.G.);

21 mferrer@icp.csic.es (M.F.).

22 Enzyme engineering has allowed not only de novo creation of active sites catalysing known 23 biological reactions with rates close to diffusion limits, but also the generation of abiological sites 24 performing new-to-nature reactions. However, catalytic advantages of engineering multiple 25 active sites into a single protein scaffold are yet to be established. Here, we report on proteins 26 with two active sites of biological and/or abiological origin, for improved natural and non-27 natural catalysis. The approach increased catalytic properties, such as enzyme efficiency, 28 substrate scope, stereo-selectivity, and optimal temperature window of an esterase when 29 containing two biological sites. Then, one of the active sites was metamorphosed into a metal-30 complex chemocatalytic site for oxidation and Friedel-Crafts alkylation reactions facilitating 31 synergistic chemo- and biocatalysis in a single protein. The transformation of 1-naphthyl acetate 32 to 1,4-naphthoquinone (conversion ca. 100%) and vinyl crotonate/benzene to 3-phenylbutyric 33 acid (≥83%; e.e. >99.9%) was achieved in one-pot by this artificial multi-functional 34 metalloenzyme.

35 The field of enzyme engineering has developed considerably over the last decade, opening great 36 potential for applications ranging from greener production processes and diagnostics to therapeutic usage and biomedicine. Directed evolution and computation-driven rational mutagenesis are fostering 37 such developments<sup>1-4</sup>. These techniques allow optimization of biocatalysts by tuning substrate 38 39 specificity and improving the activity and/or stability under operational conditions. In addition, 40 significant efforts in *de novo* enzymatic active site design are being undertaken, although directed 41 evolution and protein engineering are required to boost the activity of the original computational 42 design. The introduction of biocatalytic sites into non-catalytic protein scaffolds also opens new opportunities<sup>5-9</sup>. As such, certain artificial enzymes approach the diffusion limit while still catalysing 43 the desired reaction using a single artificial active site, with turnover rates as high as those of some 44 natural enzymes  $(1-5 \text{ s}^{-1})^{10-12}$ . 45

46 There are also examples in which catalytically competent organometallic complexes have been 47 introduced in proteins that serve as scaffolds to generate artificial metalloenzymes (ArMs). The first examples of ArMs date back to the late 1970s, when Wilson and Whitesides introduced a diphosphine 48 49 rhodium (I) biotin derivative into a streptavidin scaffold. The authors demonstrated that this achiral 50 chemocatalyst, located in the asymmetric environment of the biotin-binding site of streptavidin, was capable of chiral hydrogenation of  $\alpha$ -acetamido-acrylic acid<sup>13</sup>. However, this work, possibly owing to 51 52 the unenthusiastic conclusions drawn by the authors, did not attract the attention of the scientific 53 community. It was only the early 2000s that a resurgence of interest in ArMs began, fuelled by advances in both organometallic catalysis and protein engineering<sup>14</sup>. Since then, a large number of 54 55 ArMs, created through the docking of catalytically competent molecules into protein scaffolds by 56 covalent, supramolecular, dative, and metal substitution, have been described. While the catalytic 57 performance of such ArMs, shown to be competent for catalytic reactions including hydrolysis,

reduction, oxidation, C-C bond-forming and C-heteroatom bond-forming, has long been inferior to

- 59 that of their natural counterparts, recent efforts combining catalyst design and modern protein
- 60 engineering allowed bridging of this gap<sup>14,15</sup>. For example, the Ward group developed a directed

61 mutation strategy to produce thousands of protein variants and selected the most active one capable of


62 catalysing metathesis reactions in cells<sup>16</sup>. Additionally, the Roelfes group developed artificial copper-

63 bipyridine catalysts capable of enantioselective Friedel-Crafts alkylation by *in vivo* incorporation, in a

64 protein scaffold, of metal-binding unnatural amino acids<sup>17</sup> or by the creation of an artificial active site

- 65 capable of copper-binding<sup>18</sup>.
- Despite significant efforts directed at introducing single artificial biological<sup>5-12</sup> or abiological<sup>13-18</sup> catalytic entities into a protein scaffold, the introduction of multiple active sites, either biological or non-natural, and the analysis of the catalytic advantages it can have, is rare. The only examples are protein scaffolds with two heme, Fe-S or copper sites catalysing the same chemistry<sup>14,18-22</sup>, or a recent engineered lipase into which a catalytic metal has been introduced<sup>23</sup>. Although, this last design can potentially confer the capacity for cascade reactions, the catalysis was done in a two-step fashion, changing the reaction conditions, precluding synergistic effects.

Here, we report an approach that exploits the possibility to genetically engineer proteins with two biological actives sites, and furthermore, its expansion allowing its further metamorphosis into a protein with both biological and abiological active sites (Fig. 1). Results are presented demonstrating the broad potential and versatility of the presented procedure to create biocatalysts with improved catalytic properties, and metallo-enzymes capable of cascade reactions where an active synergy of both biological and abiological catalytic entities exists.



80

Fig. 1 General concept for engineering proteins with two active sites. The concept consists of
 the following sequential workflow. First, a target natural enzyme (*e.g.* a serine ester hydrolase in this
 study), containing a biological active site (BIO-SITE 1 in figure), is selected. Second, by applying
 Protein Energy Landscape Exploration (PELE) software, an extra potential binding pocket to
 introduce an artificial biological active site (*e.g.* a nucleophilic serine in this study) is identified, which

can be further remodelled to achieve an optimal configuration (BIO-SITE 2). Third, through the
differential affinity for a suicide phosphonate inhibitor bearing a metal-organic complex, one of the
biological sites is metamorphosed into a copper-based chemocatalytic (or abiological) site (CHEMOSITE), while the other site retains its own biological activity.

- 90
- 91 Results

#### 92 Design of a protein with two biological active sites and its catalytic advantages

93 Improving the efficiency of enzymes is rapidly becoming a necessity. One could imagine attacking the

problem by engineering more and more reactive sites into a single enzyme scaffold, which by a

95 synergetic effect may improve catalysis. We named this concept as *plurizyme* (the Latin root pluri:

96 multiplicity). However, the first trial of introducing a second artificial active site into a serine esterase

97 containing a natural one could not bring in catalytic advantages (Supplementary Note 1) $^{24}$ . Here,

98 through providing a better spatial configuration we designed a new artificial design ( $EH1_{B1}$ ;

99 Supplementary Figure 1) with boosted catalytic performance, in such a way that its incorporation to


100 the natural enzyme (EH1<sub>A1</sub>) intensified the  $k_{cat}$  (average: *ca*. 3.4-fold; *max*.: *ca*. 74-fold) and  $k_{cat}/K_m$ 


101 (average: *ca*. 94-fold; *max*.: *ca*. 5000-fold) for ester hydrolysis, increased the stereo-selectivity by *ca*.

102 1100-fold (e.e. >99.9%), and broadened by *ca*. 20°C the temperature at which the enzyme retained

103 more than 80% of the optimal (Fig. 2). It also expanded the substrate spectra, as the resulting

104 *plurizyme* with the two sites  $(EH1_{AB1})$  has the ability to hydrolyze all substrates (78, in total) that each







**Fig. 2 Bio-catalytic advantages of having two biological active sites. a**, The artificial site (EH1<sub>B1</sub>) intensifies the catalytic efficiency. Shown is the blox plot illustrating the relative increase of  $k_{cat}$  (left axis) and  $k_{cat}/K_m$  (right axis) values of the EH1<sub>AB1</sub> *plurizyme* with the two sites vs the original EH1<sub>A1</sub> enzyme with a single active site, for all substrates converted. **b**, The artificial site introduces stereo-specificity. Shown are the average E-values and e.e., determined by gas chromatography, for

- 112 the kinetic resolution of a racemic mixture of methyl (2R/S)-2-phenylpropanoate (R-specificity) by the 113 three sub-enzymes. Experimental conditions, raw data and standard deviations for these and other 114 substrates are given in Supplementary Note 2 (Supplementary Figures 2-3, Supplementary Tables 1-115 2). c, The artificial site expands the optimal temperature window. Shown are the temperature profiles 116 of the three sub-enzymes. For  $T_{out}$  determination, calculated on a continuous pH indicator assay<sup>24</sup>, 117 conditions are as follows - [protein]: 4.5 µg/ml; [glyceryl tripropionate]: 50 mM; reaction volume: 44 118  $\mu$ ; T: 4-55°C; pH: 8.0. The data, calculated from three independent assays  $\pm$  standard deviations 119 (calculated using Excel version 2019) and not fitted to any model, represent the relative percentages (%) of specific activity expressed as U mg<sup>-1</sup>, compared with the maximum. 120 121
- Together, engineering multiple active sites with identical chemistry catalyzed can thus help, through differences in specificity, affinity, turnover rates and local stabilities, intensifying the original bio-catalytic properties of, or conferring new properties (*e.g.* stereo-specificity and expanded working temperature) to, a natural enzyme, herein exemplified by a serine ester-hydrolase. For detailed description of the engineering approach, and detailed experimental and results information see Supplementary Note 2 (Supplementary Figures 2-3, Supplementary Tables 1-2).
- 128

## 129 Structural evidences of a *plurizyme* with two biological active sites

130 To prove that both active sites of our *plurizyme* ( $EH1_{AB1}$ ) are capable of substrate binding and that

131 conversion can occur in both sites, we performed a structural analysis. We obtained crystals from

132 EH1<sub>AB1</sub> diffracting at 2.1 Å resolution. These crystals were cocrystallized with the suicide inhibitor

133 methyl 4-nitrophenyl hexylphosphonate (M4-4NHP) to obtain the corresponding derivative complex,

134 with two molecules of the inhibitor bound at the catalytic Ser161 (original nucleophile) and Ser211

135 (artificial nucleophile) sites (Fig. 3a; see Supplementary Note 3, Supplementary Figures 4-6). The 4-

136 nitrophenyl phosphonate inhibitor is susceptible to nucleophilic attack by the catalytic Ser, leading to

137 covalent modification and complete inactivation of the enzyme (see Supplementary Note 4,

138 Supplementary Figure 7) $^{25,26}$ .

The solved three-dimensional structures show high flexibility in a region (which resembles but does not equal a typical *lid* of lipases) containing the two N-terminal helical regions, Pro4-Gly19 and Ala30-Gly43, which give access to the active-site pocket. Conformational changes are observed at the secondary Ser211 catalytic site, the artificially remodelled site, upon inhibitor binding, as shown in Fig. 3b, which introduce distortions in the packing arrangement within the soaked crystals, explaining the decreased resolution observed (not shown). Nevertheless, the atomic interaction of the inhibitor bound at the two sites can be depicted and is displayed in Fig. 3c-f.










Fig. 3 Crystal structure of EH1<sub>AB1</sub>. a, Cartoon of the crystallized complex coloured by B factors,
 from low (blue) to high (red) with the two bound molecules from the suicide inhibitor M4-4NHP
 represented as magenta sticks. b, Details of the comparison between the free (orange) and complexed
 (slate) EH1<sub>AB1</sub> showing the conformational changes observed in the environment of Ser211 upon
 inhibitor binding. Polder omit maps calculated at the Ser161 and Ser211 catalytic sites displayed at 3.0
 σ cut-off. c-f, Detail of the Ser161 and Ser 211 binding sites in the free (c, e) and complexed (d, f)
 crystals showing relevant distances as dashed lines.










- Fig. 4 Absorption spectra of modified and un-modified sub-enzymes. a, Incorporation of Cu<sup>2+</sup>-SI 180 (SICu) as detected by UV-vis spectroscopy. Spectra were recorded in 96-well plates using Cu<sup>2+</sup>-181 182 modified sub-enzymes (15  $\mu$ M) prepared with an excess (120  $\mu$ M) of inhibitor and Cu<sup>2+</sup> (see 183 Supplementary Methods) in a total volume of 200 µl. Modified sub-enzymes prepared with an excess 184 (120 µM) of inhibitor but without copper salt are shown as a control. **b**. The UV-vis spectra of SI and 185 Cu-modified SI inhibitor (SICu) at 15 µM in a total volume of 200 µl. Shown are average values with a standard deviation of triplicates (calculated using Excel version 2019) shown as shadows; in the case 186 187 of the control sample, the average value and standard deviation of all three sub-enzymes measured in 188 triplicate are shown.
- 189


190 By recording the cyclic voltammetry electrochemical response on 3-mercaptopropanoic acid 191 (MPA)-modified gold electrodes (Supplementary Note 6, Supplementary Figure 12), we further observed a different behaviour between the free Cu<sup>2+</sup>-organic complex and the SICu complex, which 192 shows an expected lower electrochemical reversibility due to the chelation of the Cu<sup>2+</sup> cation in the SI 193 chelating pocket (Supplementary Note 6, Supplementary Figure 13). When SICu was located in the 194 195 protein scaffold (Fig. 6a) the copper electrochemical signal became more reversible. Results not only 196 showed that the copper complex is effectively inside the corresponding sub-enzymes active sites, but 197 that the electrochemical peaks have shifted and the copper redox signals differs when located in each sub-enzyme (Fig. 6a). Such differences are better spotted in the sub-enzyme with two active sites 198  $(EH1_{AB1})$  which, due to the presence of two binding  $Cu^{2+}$  sites, has an extra increase in the signal of 199  $Cu^{2+}$  compared to sub-enzymes A1 (EH1<sub>A1</sub>) and B1 (EH1<sub>B1</sub>) which contains only one. It is also worth 200 201 pointing out that there is no electrochemical response at the free SICu potentials, suggesting that the 202 inhibitor does not leak out of the binding pocket. The recording of the oxidation of catechol also 203 showed a higher catechol oxidation activity of the  $EH1_{AB1}$ -SICu biocatalyst compared  $EH1_{A1}$ -CuSI 204 and EH1<sub>B1</sub>-CuSI (Fig. 6b), not observed in the absence of CuSI (Fig. 6b inset). Catechol did not 205 behave as electrochemical substrate and the process does not fulfil all the requirements to be 206 considered a bioelectrocatalytic oxidation process; however, the enzymes behave as an electron 207 transfer relay that allows the oxidation of catechol at its non-catalytic potential (0.25V vs Ag/AgCl; 208 see Supplementary Note 6). Impedance spectroscopy measurements were also performed using 209 catechol as the redox electrochemical probe. Impedance spectroscopy showed a similar trend for each 210 sub-enzyme: modified sub-enzymes displayed in every case a lower electron transfer resistance than 211 non-modified ones. Nyquist plots allow calculating the charge transfer resistance (Rct) between the 212 electrodes modified with each sub-enzyme and the catechol (Fig. 6c). Remarkably, the EH1<sub>AB1</sub>–SICu sub-enzyme offered a 10-fold reduction in the Rct when compared to that of EH1<sub>AB1</sub> in the absence of 213 SICu, a 3-fold reduction in the Rct when compared to that of EH1<sub>A1</sub>–SICu and a 4-fold reduction in 214 215 the Rct when compared to that of  $EH1_{B1}$ -SICu. These results suggest that the two active sites of the EH1<sub>AB1</sub> sub-enzymes contain Cu<sup>2+</sup>-organic complexes which, because their proximity, facilitates 216


- 217 intramolecular electron transfer at levels higher than those shown by modified  $EH1_{A1}$  and  $EH1_{B1}$  sub-
- enzymes containing only one site and one complex (Fig. 6c). Control experiments recorded with the
- electrodes modified with enzymes lacking CuSI, which yielded no electrochemical response of
- 220 catechol, support the need of CuSI-socketed enzymes to allow an electronic path to the electrode
- surface. Such electronic path is more likely intramolecular, as there is no sign of CuSI leakage, and an
- 222 extramolecular electron path would imply the cooperation of different enzymes, a less likely
- 223 mechanism. For detailed description of the electrochemical characterization and electrode and probe
- design see Supplementary Note 6 (Supplementary Figures 12-18).



227	Fig. 5 Electrochemical characterization of the chemo-bio catalysts. a, Electrochemical signals of
228	MPA-gold electrodes modified with (A) CuSI, (B) EH1 <sub>A1</sub> -CuSI, (C) EH1 <sub>B1</sub> -CuSI and (D) EH1 <sub>AB1</sub> -
229	CuSI. The CuSI concentration added was ca. 0.43 mM. All measurements were recorded using a 20
230	$mV \cdot s^{-1}$ scan rate and 50 mM phosphate buffer pH 6.5 electrolyte. The working electrode was a gold
231	disk with a 0.2 cm <sup>2</sup> diameter modified with an MPA SAM. The reference electrode was 3 M Ag/AgCl,
232	and the counter electrode was Pt wire. b, Oxidation of catechol (1 mM) by MPA-gold electrodes
233	modified with (A) $EH1_{A1}$ -CuSI, (B) $EH1_{B1}$ -CuSI and (C) $EH1_{AB1}$ -CuSI (process from 0.3 to 0.5 V).
234	Inset: electrochemical responses to catechol measured with MPA-gold electrodes modified with (A)
235	CuSI, (B) $EH1_{AB1}$ in absence of CuSI and (C) $EH1_{AB1}$ in presence of CuSI. <b>c</b> , Impedance spectroscopy
236	showing that EH1 <sub>AB1</sub> -CuSI presents a much lower electron transfer resistance than any other
237	combination of sub-enzymes with or without CuSI. Impedance measurements were performed using
238	catechol 1 mM, a bias potential of 0.35 V vs Ag/AgCl. The experimental setup (sub-enzyme
239	concentration ca. 0.43 mM) was the same 3-electrode configuration used for cyclic voltammetry.
240	
241	Together, results confirm that the SI herein synthesized can be used as a platform to introduce a
242	Cu <sup>2+</sup> -organic complex into our genetically engineered <i>plurizyme</i> through the elimination of the
243	methoxy group of the suicide inhibitor and the coupling of a 3'-hydroxy-[2,2'-bipyridin]-3-yl moiety
244	capable of copper binding. The bio-conjugation of two organic complexes to $\rm EH1_{AB1}$ and one to
245	$EH1_{A1}$ and $EH1_{B1}$ was also confirmed by ESI-MS (Supplementary Note 6, Supplementary Figure 19).
246	The fact that, under excess conditions, the conjugation occurs at both active sites might be a
247	disadvantage, as our primary objective was to create a <i>plurizyme</i> variant, hereafter referred to as
248	$EH1_{AB1}$ <u>chemo-biocatalyst</u> ( $EH1_{AB1C-B}$ ), in which one of the active sites is replaced by a $Cu^{2+}$ -catalyst
249	and the other remains unaltered. To remedy this shortcoming, we evaluated the possibility that both
250	sites have different affinities for the inhibitor; the different affinities for multiple other substrates (see
251	Supplementary Note 2, Supplementary Figure 2) and the differences in catalytic environments of each
252	active site (Fig. 3) indicated such a possible differentiation. This hypothesis was evaluated by
253	measuring the loss of hydrolytic activity of each sub-enzyme (EH1 <sub>A1</sub> , EH1 <sub>B1</sub> and EH1 <sub>AB1</sub> ) in the
254	presence of different concentrations of the inhibitor. As shown in Supplementary Note 7 (see
255	Supplementary Figure 20), whereas the native site could be inhibited at very low concentrations (ca. 5
256	$\mu$ M), the artificial one was only inhibited at concentrations above 35 $\mu$ M. On the basis of the
257	differential active-site affinity, a dose-dependent inhibition strategy was designed that allowed the
258	specific bio-conjugation of the Cu <sup>2+</sup> -organic complex to Ser161 but not to Ser 211 (see Supplementary
259	Methods; Supplementary Note 7, Supplementary Figure 21). As such, an $EH1_{AB1}$ variant in which the
260	Cu <sup>2+</sup> -organic complex was bio-conjugated at the native active site but not the artificial site could be
261	obtained (Fig. 6), with a coupling efficiency and purity higher than 98% (see Supplementary Note 7,

Supplementary Figures 22-23). This result was confirmed by applying this strategy to each of the subenzymes and by confirming the increase in mass by ESI-MS and the  $\lambda_{max}$  at 386 nm by UV/vis absorption spectroscopy (see Supplementary Note 7, Supplementary Figures 22-24). As an additional experimental confirmation, we cocrystallized EH1<sub>AB1</sub> with the CuSI complex (see Supplementary Note 3, Supplementary Figure 6). Despite its moderate resolution (2.79 Å), the electron density confirmed binding of the ligand only to the native active site. However, the poor quality at the copper-bipyridine moiety impeded modelling of this portion, which might be attributed to disorder or partial occupancy.





- 274
  - as follows: green, the artificial enzymatic site; red: the native site; black: copper-bipyridine molecule
- 275 placed in the native site. In grey colour, the one-pot conversion of 1-naphthyl acetate (1) to naphthol
- 276 (2) by the enzymatic site and its further oxidation to 1,4-naphthoquinone (3) by the metal-complex site 277 are illustrated. b, Model one-pot conversion of vinyl crotonate (4) to crotonic acid (5) by the

enzymatic site, and its further Friedel-Crafts alkylation to  $\beta$ -phenylbutyric acid (7) by the metal-

complex site in the presence of benzene (6).

- 278
- 279
- 280

#### 281 Synergistic catalysis of the biological with the abiological active site

282 The catalytic activity of  $EH1_{ABIC-B}$  (Fig. 6a) was evaluated in 2 cascade reactions, which consist of the 283 enzymatic hydrolysis of an ester, followed by a copper-bipyridine oxidation (Fig. 6a, in grey colour) 284 or a Friedel-Crafts alkylation reaction (Fig. 6b). In the first target reaction, enzymatic hydrolysis of 285 ester 1 will produce alcohol 2, which may be oxidized by the copper-bipyridine catalyst to quinone 3. 286 This reaction was selected based on the fact that electrochemical tests demonstrated an electron 287 transfer capacity by copper-bipyridine. Ester 1 was selected because it is a polyphenol ester for which 288 the artificial esterase site shows a high conversion rate (see Supplementary Note 2, Supplementary 289 Figure 2, Supplementary Table 1). In the second target reaction, enzymatic hydrolysis of ester 4 will produce the alkenyl fatty acid 5, which in the presence of benzene (6) may yield  $\beta$ -phenylbutyric acid 290 (7)<sup>40</sup>. This model reaction was selected because copper-bipyridine catalysts have been shown to 291 292 perform vinylogous Friedel-Crafts alkylation reactions<sup>17,18</sup>; ester **4** was selected because it was well 293 converted by the artificial site (see Supplementary Note 2, Supplementary Figure 2, Supplementary

```
294
       Table 1), and the resulting hydrolysis product can be coupled with benzene.
```

295 The first reaction (Fig. 6a) was carried out at pH 8.0 and 25°C using 10 mM ester 1. Using a 296 modified protein not containing  $Cu^{2+}$ , no quinone **3** was formed, but formation of alcohol **2** (100%) 297 conversion) was found (Fig. 7a). This result was expected because the only active site was the 298 biocatalytic site. However, in the presence of the chemo-biocatalyst, the conversion to quinone **3** 299 reached 100% after a 2 h reaction (Fig. 7b). The second reaction (Fig. 6b) was carried out at 4°C for 3 days following conditions described elsewhere<sup>17,18</sup>. Using a modified protein not containing Cu<sup>2+</sup>, only 300 301 crotonic acid (5) was formed, and benzene (6) remained without consumption (Fig. 8a), whereas in the 302 presence of the chemo-biocatalyst, the conversion reached 83% for product 7 after 3 days (Fig. 8b).

- 303 The high activity level of the artificial ester-hydrolase active site (Fig. 2c; see Supplementary Note 2,
- 304 Supplementary Figure 3) at 4°C helps achieve a high conversion rate for the enzymatic step and the
- 305 concomitant production of product 7. Interestingly, the product was obtained with a 99% e.e. for (S)-3-
- 306 phenylbutyric acid (see Supplementary Methods). Reaction mixtures obtained in all cases were
- 307 analysed by ESI-MS (see Supplementary Methods), and the existence of the reaction products was
- 308 confirmed in each case. We would like to mention that the reaction conditions were not optimized.





Fig. 7 One-pot synthesis of 1,4-naphthoquinone from 1-napthyl acetate catalysed by EH1<sub>ABIC</sub>.
 B. a, Control reaction performed with modified sub-enzyme not containing Cu<sup>2+</sup>. b, Reaction in the
 presence of EH1<sub>ABIC-B</sub> containing Cu<sup>2+</sup>. Reaction conditions as follows: - [1-naphthyl acetate]: 10 mM;
 [sub-enzyme]: 80 μM; T: 25°C; pH: 7.0. Reactions were performed in triplicates with average value
 and standard deviations (calculated using Excel version 2019) indicated.



316 Fig. 8 One-pot synthesis of 3-phenylbutyric acid from vinyl crotonate and benzene catalysed

317 by EH1<sub>AB1C-B</sub>. a, Control reaction performed with modified sub-enzyme not containing  $Cu^{2+}$ . b,

318 Reaction in the presence of  $EH1_{AB1C-B}$  containing  $Cu^{2+}$ . Reaction conditions as follows: - [vinyl

- 319
- 320

crotonate]: 10 mM; [benzene]: 10 mM; [sub-enzyme]: 80 μM; T: 4°C; pH: 7.0. Crotonic acid (intermediate reaction product) is not detected under our analytical method and is not shown. Reactions were performed in triplicates with average value and standard deviations (calculated using Excel version 2019) indicated.

322 323

324 The above two examples demonstrated that a protein scaffold with both biological and abiological 325 sites is capable of performing hydrolytic-oxidative and hydrolytic-alkylation one-pot reactions with 326 excellent conversion and enantio-selectivity. From a catalytic point of view, the approach for creating 327 such hybrid catalysts opens novel opportunities compared to previous designs of bio-inspired chemo-328 catalysts, in which the protein scaffold is mostly a container of a transition metal-complex whose properties are influenced by the microenvironment where it is positioned within the protein scaffold<sup>18</sup>. 329 Here, the enzyme also contributes to the catalytic activity. Also, compared to the recent design of a 330 lipase with a  $Cu^{2+}$  catalyst<sup>23</sup>, where the synergy is not direct and requires, after a first hydrolytic step 331 mediated by the lipase activity, a second reduction reaction just requiring Cu<sup>2+</sup> and NaBH<sub>4</sub> added to a 332 333 concentration (ca. 15 mg/ml) which may compromise protein integrity and catalyst reutilization<sup>41</sup>; 334 thus, in the second reaction the protein does not play an active catalytic role except to immobilize the  $Cu^{2+}$  catalyst. In contrast, in our design the reaction is done in one step allowing synergetic catalysis 335 336 and easy handling; also the cascade reaction produce products in high e.e. that cannot be achieved by 337 the metal cofactor without the protein scaffold.

338 From a methodological point of view, the strategy designed herein to introduce transition metal-339 complexes can complement the ones previously described, including the metal-binding utilizing cysteine conjugation<sup>18,23</sup> or unnatural amino acids<sup>17</sup>. It is worth mentioning the following advantages. 340 341 First, our strategy, requiring only side chain replacement, is expected to be versatile in that it can 342 potentially be applied to a large range of enzymes. Second, through the application of PELE 343 simulations, we ensure that the metal-catalyst is located in an area capable of substrate binding<sup>42</sup>. 344 Third, the metal-catalyst is incorporated through a well stablished suicide inhibition mechanism only 345 requiring the presence of a nucleophilic serine. While introducing two nucleophilic serine may create 346 selectivity problems that do not exist for other bio-conjugation approaches<sup>18,23</sup>, it is also true that both 347 may have different affinities by which one can control the coupling specificity, as it was shown in the 348 *plurizyme* herein designed. It is also plausible that both sites may have different specificity for other 349 metal-complexes allowing specific bio-conjugation, yet to be investigated, or that in other *plurizymes* 350 to be developed such selectivity problems may not occur because different active site configurations. 351 For additional remarks see Supplementary Note 7.

352

#### 353 Conclusions

Recent progress in (bio)chemical sciences has enabled the design and production of protein scaffolds artificially endowed with either biocatalytic or chemocatalytic activities. While this is plausible when a single artificial catalytic entity is introduced into a protein scaffold, it is however challenging to
introduce multiple sites and activities, including natural and non-natural ones. To what extend can
additional sites and activities, either biological and/or abiological, intensify the catalytic performance
of protein scaffolds? Overcoming this challenge and finding answers to this question would allow the
design of more efficient biocatalysts with improved natural activities and multi-catalytic systems for

361 performing non-natural concerted cascade reactions.

362 Here, an approach to design catalytically active proteins equipped with two enzymatic active sites 363 or an enzymatic and a chemocatalytic site is described, and consists of the following sequential 364 workflow: production of a genetically engineered *plurizyme* with two distinct active sites (e.g. two 365 sites supporting ester hydrolysis in this study) through structure-based modelling – chemical design of 366 a synthetic catalytic suicide inhibitor capable of coordinating a transition metal ion - metamorphosis 367 of one of the serine hydrolytic biological sites into a versatile metal-complex chemocatalytic site 368 through suicide inhibition. We hypothesized this approach may provide technical advantages, 369 including expansion of the diversity of artificial catalysts, and new catalytic opportunities. This was 370 showed by a first example demonstrating that the catalytic properties of a natural serine hydrolase can 371 be significantly boosted by adding an artificial site with an appropriate catalytic configuration, because 372 the additive effect of the two biological (natural and artificial) sites. Results provided in 373 Supplementary Note 8 (Supplementary Figures 25-28, Supplementary Table 3) further demonstrated 374 that the *plurizyme* approach and the catalytic enhancement associated to the introduction of multiple 375 biological sites is reproducible and can be easily extended to other serine ester-hydrolase. A second example is also exemplified by the design of hybrid homogeneous catalysts integrating multi-catalytic 376 377 units in one, which are capable of performing chemical and biological catalysis in synergy (e.g., e.g.)

- 378 sequential reactions) with excellent conversion and enantio-selectivity. Results provided in
- 379 Supplementary Note 9 (Supplementary Figures 29-31, Supplementary Table 4) further demonstrated
- that our design offers advantages compared to traditional multi-catalyst systems $^{23}$ , as the co-
- 381 localization of both biological and abiological catalytic entities in a single scaffold was shown to
- 382 favour substrate and product transfer of one to another and to expand the performance under
- 383 conditions at which the native catalysts are sub-optimal.
- 384

## 385 Methods


- 386 A full description of the methods is available in the Supplementary Information (see Supplementary
- 387 Methods, and Supplementary Note 10, Supplementary Figures 32-36).
- 388
- **Data availability**: The atomic coordinates have been deposited in the Protein Data Bank under
- accession numbers 6I8F, 6RB0 and 6RKY. All other data is available from the authors upon
- 391 reasonable request.
- 392


393	References		
394	1.	Bren, K. L. Engineered biomolecular catalysts. J. Am. Chem. Soc. 139, 14331-14334 (2017).	
395	2.	Ebert, M. C. & Pelletier, J. N. Computational tools for enzyme improvement: why everyone	
396		can - and should - use them. Curr. Opin. Chem. Biol. 37, 89-96 (2017).	
397	3.	Arnold, F. H. Directed evolution: Bringing new chemistry to life. Angew Chem. Int. Ed. Engl.	
398		<b>57</b> , 4143-4148 (2018).	
399	4.	Acebes, S. et al. Rational enzyme engineering through biophysical and biochemical modeling.	
400		ACS Catal. 6, 1624-1629 (2016).	
401	5.	Seelig, B. & Szostak, J. W. Selection and evolution of enzymes from a partially randomized	
402		non-catalytic scaffold. Nature 448, 828-831 (2007).	
403	6.	Jiang, L. et al. De novo computational design of retro-aldol enzymes. Science 319, 1387-1391	
404		(2008).	
405	7.	Richter, F. et al. Computational design of catalytic dyads and oxyanion holes for ester	
406		hydrolysis. J. Am. Chem. Soc. 134, 16197-16206 (2012).	
407	8.	Rufo, C. M. et al. Short peptides self-assemble to produce catalytic amyloids. Nat. Chem. 6,	
408		303-309 (2014).	
409	9.	Moroz, Y. S. et al. New tricks for old proteins: single mutations in a nonenzymatic protein give	
410		rise to various enzymatic activities. J. Am. Chem. Soc. 137, 14905-14911 (2015).	
411	10.	Blomberg, R. et al. Precision is essential for efficient catalysis in an evolved Kemp eliminase.	
412		Nature 503, 418-421 (2013).	
413	11.	Khersonsky, O. et al. Optimization of the in-silico-designed Kemp eliminase KE70 by	
414		computational design and directed evolution. J. Mol. Biol. 407, 391-412 (2011).	
415	12.	Röthlisberger, D. et al. Kemp elimination catalysts by computational enzyme design. Nature	
416		<b>453</b> , 190-195 (2008).	
417	13.	Wilson, M. E. & Whitesides, G. M. Conversion of a protein to a homogeneous asymmetric	
418		hydrogenation catalyst by site-specific modification with a diphosphinerhodium(I) moiety. J.	
419		Am. Chem. Soc. 100, 306-307 (1978).	
420	14.	Dydio, P. et al. An artificial metalloenzyme with the kinetics of native enzymes. Science, 354,	
421		102-106 (2016).	
422	15.	Lewis, J. C. Artificial metalloenzymes and metallopeptide catalysts for organic synthesis. ACS	
423		Catal. 3, 2954-2975 (2013).	
424	16.	Jeschek, M. et al. Directed evolution of artificial metalloenzymes for in vivo metathesis. Nature	
425		<b>537</b> , 661-665 (2013).	
426	17.	Drienovská, I. et al. Novel artificial metalloenzymes by in vivo incorporation of metal-binding	
427		unnatural amino acids. Chem Sci. 6, 770-776 (2015).	
428	18.	Bos, J. et al. Enantioselective artificial metalloenzymes by creation of a novel active site at the	
429		protein dimer interface. Angew. Chem. Int. Ed. Engl. 51, 7472-7475 (2012).	


- Lin, Y.-W. et al. Rational design of heterodimeric protein using domain swapping for
  myoglobin. *Angew. Chem. Int. Ed.* 54, 511–515 (2015).
- 432 20. Farid, T. A. Elementary tetrahelical protein design for diverse oxidoreductase functions. *Nat.*433 *Chem. Biol.* 9, 826-833 (2013).
- Roy, A. et al. De novo design of an artificial bis[4Fe-4S] binding protein. *Biochemistry* 2013,
  52, 7586-7594 (2013).
- 436 22. Tebo, A. G. & Pecoraro, V. L. Artificial metalloenzymes derived from three-helix bundles.
  437 *Curr. Opin. Chem. Biol.* 25, 65-70 (2015).
- 438 23. Felice, M. et al. Synthesis of a heterogeneous artificial metallolipase with chimeric catalytic
  439 activity. *Chem. Commun. (Camb)* 51, 9324-9327 (2015).
- 440 24. Santiago, G. et al. Rational engineering of multiple active sites in an ester hydrolase.
  441 *Biochemistry* 57, 2245-2255 (2018).
- 442 25. Zollner H. Handbook of enzyme inhibitors (Wiley-VCH Verlag GmbH, 1999).
- 443 26. Myers, D. K. Competition of the aliesterase in rat serum with the pseudo cholinesterase for
  444 disopropyl fluorophosphonate. *Science* 115, 568-570 (1952).
- 445 27. Beller M., Renken A. & van Santen R. A. *Catalysis: from principles to applications* (Wiley446 VCH Verlag GmbH, 2012).
- 28. Schwizer, F. et al. Artificial metalloenzymes: reaction scope and optimization strategies. *Chem. Rev.* 118, 142-231 (2018).
- Wang, T. et al. Rational redesign of the active site of selenosubtilisin with strongly enhanced
  glutathione peroxidase activity. *J. Catal.* 359, 27-35 (2018).
- 451 30. Hoque, M. A. et al. Stepwise loop insertion strategy for active site remodeling to generate novel
  452 enzyme functions. *ACS Chem. Biol.* 12, 1188-1193 (2017).
- 453 31. Payer, S. E. et al. A rational active-site redesign converts a decarboxylase into a C=C hydratase:
  454 "Tethered Acetate" supports enantioselective hydration of 4-hydroxystyrenes. *ACS Catal.* 8,
  455 2438-2442 (2018).
- Zastrow, M. L. & Pecoraro, V. L. Influence of active site location on catalytic activity in de
  novo-designed zinc metalloenzymes. J. Am. Chem. Soc. 135, 5895-5903 (2013).
- 458 33. Ross, M. R. et al. Histidine orientation modulates the structure and dynamics of a de novo
  459 metalloenzyme active site. J. Am. Chem. Soc. 137, 10164-10176 (2015).
- 460 34. Der, B. S., Edwards, D. R. & Kuhlman, B. Catalysis by a de novo zinc-mediated protein
  461 interface: implications for natural enzyme evolution and rational enzyme engineering.
- 462 *Biochemistry* **51**, 3933-3940 (2012).
- 463 35. Khare, S. D. et al. Computational redesign of a mononuclear zinc metalloenzyme for
  464 organophosphate hydrolysis. *Nat. Chem. Biol.* 8, 294-300 (2012).
- 36. Zastrow, M. L. et al. Hydrolytic catalysis and structural stabilization in a designed
  metalloprotein. *Nat. Chem.* 4, 118-123 (2012).


467	37.	Dydio, P. et al. An artificial metalloenzyme with the kinetics of native enzymes. Science 354,			
468		102-106 (2016).			
469	38.	Zandonella, G. et al. Interactions of fluorescent triacylglycerol analogs covalently bound to the			
470		active site of a lipase from Rhizopus oryzae. Eur. J. Biochem. 262, 63-69 (1999).			
471	39.	Tokuriki, N. et al. Diminishing returns and tradeoffs constrain the laboratory optimization of an			
472		enzyme. Nat. Commun. 3, 1257 (2012).			
473	40.	Koelsch C. F., Hochmann H., Le Claire C. D. The Friedel-Crafts reaction with cinnamic,			
474		crotonic, and β-chlorocrotonic acids. J. Am. Chem. Soc. 65, 59-60 (1943).			
475	41.	Blanco R. M. & Guisán J. M. Stabilization of enzymes by multipoint covalent attachment to			
476		agarose-aldehyde gels. Borohydride reduction of trypsin-agarose derivatives. Enzyme Microb.			
477		Technol. 11, 360-366 (1989).			
478	42.	Lecina D., Gilabert J. F. & Guallar V. Adaptive simulations, towards interactive protein-ligand			
479		modeling. Sci Rep. 7, 8466 (2017).			
480					
481	Acknowledgements				
482	This work was funded by grant 'INMARE' from the European Union's Horizon 2020 (grant				
483	agreement no. 634486), grants PCIN-2017-078 (within the Marine Biotechnology ERA-NET),				
484	CTQ2016-79138-R, BIO2016-76601-C3-1-R, BIO2016-76601-C3-3-R, BIO2017-85522-R, RTI2018-				
485	095166-B-I00, and RTI2018-095090-B-100 from the Ministerio de Economía y Competitividad,				
486	Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI),				
487	Fondo Europeo de Desarrollo Regional (FEDER) and European Union (EU). P.N.G. and R.B.				
488	acknowledge the support of the UK Biotechnology and Biological Sciences Research Council				
489	(BBSRC; grant No. BB/M029085/1) and the Centre of Environmental Biotechnology Project and the				
490	Supercomputing Wales project, which are partly funded by the European Regional Development Fund				
491	(ERDF) via the Welsh Government. The authors gratefully acknowledge financial support provided by				
492	the ERDF. C. Coscolín thanks the Ministerio de Economía y Competitividad and FEDER for a PhD				
493	fellowship (Grant BES-2015-073829). Jose L. Gonzalez-Alfonso thanks the support of Spanish				
494	Ministry of Education, Culture and Sport through the National Program FPU (FPU17/00044). I. Cea-				
495	Rama thanks the Regional Government of Madrid for a fellowship (PEJ_BIO_AI_1201). Authors				
496	would like to acknowledge Sergio Ciordia and María C. Mena for MALDI-TOF/TOF analysis. We				
497	thank the staff of the European Synchrotron Radiation Facility (ESRF), Grenoble, France, for				
498	providing access and for technical assistance at beamline ID30A-1/MASSIf-1 and the Synchrotron				
499	Radiation Source at Alba (Barcelona, Spain) for assistance at BL13-XALOC beamline. Authors would				
500	like to acknowledge also to María J. Vicente and Maite A. Pascual at the Servicio Interdepartamental				
501	de In	vestigación (SIDI) from the Autonomous University of Madrid for the ESI-MS analyses.			
502					
503	Auth	nor contributions			


- 504 SA, GS and IC-R contributed equally to this work. The manuscript was written through contributions
- 505 of M. Ferrer, V. Guallar, J. Sanz-Aparicio and P. Shahgaldian. All authors have given approval to the
- 506 final version of the manuscript. SA, CC, LF-L, MM-M, HM and PNG contributed to site-directed
- 507 mutagenesis and protein expression, purification and characterization. JM and AKR coordinated, in
- 508 collaboration with MF, the synthesis of suicide inhibitor. RB contributed to the biochemical data
- analysis. DR and CB contributed GC analysis for enantioselectivity determination. JLG-A and FJP
- 510 performed HPLC analysis of the reaction products. GG and VG conducted the PELE simulations and
- 511 molecular dynamics. MP contributed together with SA and LF-L to the electrochemical measurement.
- 512 IC-R and JS-A performed the crystallization and X-ray structure determination. MB contributed to
- 513 protocol development for the inhibition procedure. MF and VG conceived the *plurizyme* work, and
- 514 MF and PS conceived the metamorphosis of the enzymatic to chemical catalyst. MF wrote the initial
- 515 draft of the manuscript, which was further written through contributions of VG, JS-A and PS.
- 516 Competing interests
- 517 The authors declare no competing interests.
- 518
- 519 Additional information
- 520 **Supplementary information** in available for this paper.
- 521 Materials and correspondence should be sent to M. F., V. G. or J. S-A.




















b

а

